Please amend the application as follows:

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Amendments to Claims:

- 1-20. (Previously Cancelled)
- 21. (Previously Added) A method for treatment of diseases influenced by the inhibition of NF-κB production comprising:

administering a composition comprising an R-enantiomer of an arylpropionic acid or a derivative thereof which does not metabolize to CoA thioesters selected from R-flurbiprofen, R-ketoprofen, R-naproxen, R-tiaprofenic acid, and/or R-fenoprofen to a human subject suffering from a disease influenced by the inhibition of NF-kB production,

wherein the composition comprises the R-arylpropionic acid or the R-arylpropionic acid derivative in an amount from 100 to 1000 mg/dose.

- 22. (Previously Added) A method according to claim 21, wherein the R-arylpropionic acid or R-arylpropionic acid derivative is essentially free of S-arylpropionic acids or S-arylpropionic acid derivatives.
- 23. (Previously Added) A method according to claim 21, wherein the R-arylpropionic acid or R-arylpropionic acid derivative is present as a salt of an alkali metal, an alkaline earth metal, an ammonium, an amino acid, or aluminum.
- 24. (Previously Added) A method according to claim 23, wherein the salt is an amino acid salt selected from the group consisting of a lysinate salt, a megluminate salt, a trometamine salt and an arginate salt.
- 25. (Currently Amended) A method according to claim 21, wherein the composition comprises a medicament is part of a medicament for oral, rectal, transdermal,

intrathecal, epi or peridural, or parenteral, namely subcutaneous, intramuscular or intravenous adminsitration.

- 26. (Previously Added) A method according to claim 25, wherein the medicament comprises at least one adjuvant and/or a carrier material.
- 27. (Previously Added) A method according to claim 25, wherein the medicament comprises an orally usable form.
- 28. (Previously Added) A method according to claim 27, wherein the orally usable form comprises a tablet or a dragee.
- 29. (Previously Added) A method according to claim 21, wherein the Rarylpropionic acid or R-arylpropionic acid derivative is used in timed-release form.
- 30. (Previously Added) A method according to claim 29, wherein the timed-release form comprises a rapidly inflowing form.
- 31. (Previously Added) A method according to claim 29, wherein the timed-release form comprises a retardedly inflowing form.
- 32. (Previously Added) A method according to claim 29, wherein the timed-release form comprises a combined rapidly and retardedly inflowing form.
- 33. (Currently Amended) A method according to claim 21, wherein the method for treatment of diseases influenced by the inhibition of NF-κB production comprises treatment of pain due to at least one of a rheumatic disease, asthma, a tumor, an immune disease, shock, an inflammatory intestinal disease, radiation damage, arteriosclerosis and rejection reactions after tissue and organ transplantation.
- 34. (Previously Added) A method according to claim 33, wherein the inflammatory intestinal disease comprise crohn's disease or colitis ulcerosa.

- 35. (Newly Added) A method according to claim 21, wherein the composition comprises the R-arylpropionic acid or the R-arylpropionic acid derivative in an amount from 1000 mg/dose or higher.
- 36. (Newly Added) A method according to claim 21, wherein the composition comprises the R-arylpropionic acid or the R-arylpropionic acid derivative in an amount between 100 mg/dose and 500 mg/dose.
- 37. (Newly Added) A method according to claim 21, wherein the composition comprises the R-arylpropionic acid or the R-arylpropionic acid derivative in an amount from 200 to 1000 mg/dose.
- 38. (Newly Added) A method according to claim 21, wherein the composition comprises the R-arylpropionic acid or the R-arylpropionic acid derivative in an amount from 200 mg/dose or higher.
- 39. (Newly Added) A method for treatment of diseases influenced by the inhibition of NF-κB production comprising:

identifying a human subject suffering from a disease influenced by the inhibition of NF-κB production;

administering a composition comprising an R-enantiomer of an arylpropionic acid or a derivative thereof which does not metabolize to CoA thioesters selected from R-flurbiprofen, R-ketoprofen, R-naproxen, R-tiaprofenic acid, and/or R-fenoprofen to the human subject suffering from a disease influenced by the inhibition of NF-kB production,

wherein the composition comprises the R-arylpropionic acid or the R-arylpropionic acid derivative in an amount from 100 to 1000 mg/dose.